CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The Resmed CDI (ASX:RMD) share price bounced 6.5% higher today following the release of its Q3 results. Resmed and CSL Limited (ASX:CSL) seem good value relative to Cochlear Limited (ASX:COH).
The CSL Limited (ASX: CSL) share price is up 15% in one year. But consensus says the CSL share price is still 18% undervalued…
Nathan Bell, Head of Research at Intelligent Investor, joins Owen Rask on The Australian Investors Podcast to talk about global markets, ING Groep and Universal Music Group.
The CSL Limited (ASX:CSL) share price is under the spotlight after announcing its FY23 half-year result, which included good growth.
The Australian share market or S&P/ASX 200 (INDEXASX: XJO) is expected to open higher on Tuesday, according to SPI 200 futures contracts in Sydney.
The Australian share market or S&P/ASX 200 (INDEXASX: XJO) opened Friday’s ASX trading session slightly higher. CBA shares and BHP shares were again a focus on share investors.
The S&P/ASX 200 (INDEXASX: XJO) is expected to open lower on Thursday, with ASX 200 futures pointing lower. Redbubble (ASX:RBL) was deep red on Wednesday.
Get some top ASX share ideas for 2023. Wesfarmers Ltd (ASX:WES), Lovisa Ltd (ASX:LOV), TechnologyOne (ASX:TNE), CSL Ltd (ASX:CSL) and BHP Group Ltd (ASX:BHP) make this year’s list.
The CSL Limited (ASX:CSL) share price is down after it was announced the company’s leader, Paul Perreault, is stepping down.
